Researchers from the Abramson Cancer Center of the University of Pennsylvania described a death receptor pathway in cancer cells that has a primary role in its response to CAR-T cells.
Six months after winning approval from the U.S. Food and Drug Administration, Bayer announced that Nubeqa (darolutamide) posted stunning overall survival results by delaying the growth of tumors in men with non-metastatic castration-resistant prostate cancer.
Biogen reported full-year 2019 financial results, citing total revenues of $14.378 billion, an increase of 7% from the previous year.
Pharma companies from across the globe provide updates on their pipelines and business.
The best-known genetic marker for Alzheimer’s disease is ApoE4 – a form of apolipoprotein E – which is a protein involved in repairing neurons injured by aging, stroke or other reasons.
Researchers developed a type of nanoparticle that can “eat debris” related to the plaques that cause heart attacks.
Spring Bank Pharmaceuticals, based in Hopkinton, Massachusetts, is discontinuing development of inarigivir soproxil for chronic hepatitis B virus (HBV).
Researchers at Technical University of Munich (TUM) recently developed a gene therapy that might cure Duchenne muscular dystrophy.
Incyte’s ruxolitinib cream hit the drug’s primary endpoint in the Phase III TRuE-AD2 trial of atopic dermatitis in adolescents and adults. Incyte and Eli Lilly announced topline results from the Phase III trial (FREEZE-AD4) of baricitinib in topical corticosteroids for the treatment of adults with moderate to severe atopic dermatitis who did not respond to treatment with cyclosporine.
In drug development, assets are often aimed at a specific disease target or pathway, similar to a bullet fired from a gun. The idea of going after one precise target though, may not be the best solution for treating the totality of diseases, though. What may be more effective in the long run, is hitting a disease along multiple target lines. That is the idea at Cambridge, Mass.-based Immuneering.
